View Older Stories View More Recent Stories

Jul 24, 2019 04:48PM Bristol-Myers Squibb (BMY) Part 1 of Phase 3 CheckMate -227 Trial Met Primary Endpoint
Jul 24, 2019 04:16PM Bristol-Myers Squibb Provides Update on Part 2 of CheckMate -227
Jul 24, 2019 04:16PM Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
Jul 18, 2019 06:35AM Bristol-Myers Squibb (BMY), Bayer & Ono Pharma Report Collaboration Agreement to Investigate Stivarga (regorafenib) & Opdivo (nivolumab) as Combination Therapy
Jul 18, 2019 06:32AM Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients wit
Jul 18, 2019 06:30AM Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients Wit
Jul 1, 2019 05:17AM Bristol-Myers Squibb Completes Divestment of UPSA
Jun 24, 2019 07:02AM Bristol-Myers Squibb (BMY) is Planning Divestiture of OTEZLA to Get FTC Clearance for Celgene (CELG) Deal
Jun 24, 2019 07:00AM Bristol-Myers Squibb (BMY) CheckMate -459 Study Evaluating Opdivo as First-Line Treatment for Patients with Unresectable HCC Did Not Meet Primary Endpoint
Jun 24, 2019 06:59AM Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
Jun 24, 2019 06:59AM Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Jun 19, 2019 07:01AM Catalent (CTLT) Reports Acquisition of Bristol-Myers Squibb (BMY) Manufacturing Facility in Anagni, Italy
Jun 19, 2019 06:59AM Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Jun 19, 2019 06:59AM Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Jun 14, 2019 06:59AM Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Jun 13, 2019 04:38PM Bristol-Myers Squibb Announces Dividend
Jun 13, 2019 04:30PM New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients
Jun 6, 2019 06:59AM Bristol-Myers Squibb to Announce Results for Second Quarter 2019 on July 25, 2019
Jun 5, 2019 07:02AM Bristol-Myers Squibb (BMY) Announces Leadership Team Upon Completion of Pending Merger with Celgene (CELG)
Jun 5, 2019 06:59AM Bristol-Myers Squibb Announces Post-Closing Leadership Team
Jun 4, 2019 12:23PM Bristol-Myers Squibb to Take Part in Goldman Sachs 40th Annual Global Healthcare Conference
Jun 3, 2019 02:16PM Bristol-Myers Squibb (BMY) Announces Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with Opdivo and Yervoy
Jun 3, 2019 02:15PM Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab)
Jun 3, 2019 07:03AM Bristol-Myers Squibb (BMY) Announces First Presentation of Results for Opdivo Plus Yervoy Combination in Advanced HCC at ASCO
Jun 3, 2019 06:59AM Bristol-Myers Squibb Announces First Presentation of Results for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination in Advanced Hepatocellular Carcinoma at ASCO 2019
May 16, 2019 04:15PM Bristol-Myers Squibb to Present New Data on 20 Types of Cancer from Across its Oncology Portfolio at ASCO and EHA 2019
May 14, 2019 07:15AM Award-Winning Actor and Producer Sterling K. Brown Joins Bristol-Myers Squibb in Effort to Share Stories of What It’s Like to Live with Cancer Today
May 14, 2019 06:59AM Bristol-Myers Squibb to Take Part in the UBS Global Healthcare Conference
May 9, 2019 07:01AM Bristol-Myers Squibb (BMY) Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of OS with Opdivo Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated GBM
May 9, 2019 06:59AM Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated
Apr 25, 2019 06:59AM Bristol-Myers Squibb Reports First Quarter Financial Results
Apr 12, 2019 10:48AM Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Apr 11, 2019 06:59AM Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award
Apr 2, 2019 01:03PM Bristol-Myers Squibb (BMY) Announces Long-Term Survival Results from Opdivo in Lung Cancer
Apr 2, 2019 01:00PM Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
Mar 29, 2019 01:33PM Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
Mar 29, 2019 11:14AM Bristol-Myers Squibb (BMY) Confirms ISS and Glass Lewis Recommend Shareholders Vote for Proposed Merger with Celgene (CELG)
Mar 29, 2019 11:13AM Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
Mar 25, 2019 07:02AM Bristol-Myers Squibb (BMY) Board Provides Open Letter Shareholder Regarding Merger Agreement with Celgene Corp. (CELG)
Mar 25, 2019 06:59AM Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Mate
Mar 19, 2019 07:00AM Bristol-Myers Squibb (BMY) Highlights Significant Benefits of Pending Transaction with Celgene (CELG)
Mar 19, 2019 06:59AM Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
Mar 17, 2019 11:45AM AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Corona
Mar 12, 2019 02:01AM Biocartis Group NV: Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies
Mar 12, 2019 02:00AM Biocartis Group NV: Biocartis and Bristol-Myers Squibb Sign Collaboration Agreement for MSI Testing with Immuno-Oncology Therapies
Mar 7, 2019 05:22PM Bristol-Myers Squibb Announces Dividend
Mar 7, 2019 06:59AM Bristol-Myers Squibb to Announce Results for First Quarter 2019 on April 25, 2019
Mar 6, 2019 04:58PM Bristol-Myers Squibb to Take Part in the Barclays 2019 Global Healthcare Conference
Mar 6, 2019 07:10AM Bristol-Myers Squibb (BMY) Files Investor Presentation, Letter From Board Related to Pending Celgene (CELG) Deal
Mar 6, 2019 06:59AM Bristol-Myers Squibb Files Investor Presentation and Board of Directors Sends Letter to Shareholders Regarding Pending Transaction with Celgene
View More Recent Stories View Older Stories